Suppr超能文献

布洛芬、非诺洛芬钙、萘普生和托美丁钠治疗骨关节炎的四向、多中心、交叉试验:比较临床概况。

Four-way, multicenter, crossover trial of ibuprofen, fenoprofen calcium, naproxen, and tolmetin sodium in osteoarthritis: comparative clinical profiles.

作者信息

Caldwell J R, Crain D, Hoffmeister R T, Kantrowitz F, Lloyd R J, Nussdorf R T, Schmid F R, Repice M R

出版信息

South Med J. 1983 Jun;76(6):706-11. doi: 10.1097/00007611-198306000-00006.

Abstract

One hundred forty-one subjects with osteoarthritis completed this double-blind, multicenter, crossover trial comparing four nonsteroidal anti-inflammatory (NSAI) agents after single-blind aspirin stabilization. Preferences of both patients and physicians showed the following rank order from most to least preferable: tolmetin sodium, naproxen, ibuprofen, fenoprofen calcium. By all but three of more than 20 measures of efficacy, tolmetin sodium and naproxen were the more effective pair and fenoprofen calcium and ibuprofen the less effective pair of the four. Eight of nine measures of tolerability suggested the following rank order from best to worst tolerated: ibuprofen, naproxen, tolmetin sodium, fenoprofen calcium, aspirin. Few differences among the newer NSAI agents compared in this study achieved statistical significance. Nevertheless, the tolerability-efficacy relationships that emerge from studies of this type can help to define rational approaches to the use of these drugs in rheumatic diseases.

摘要

141名骨关节炎患者完成了这项双盲、多中心、交叉试验,该试验在单盲使用阿司匹林稳定病情后,比较了四种非甾体抗炎药(NSAI)。患者和医生的偏好显示出以下从最优选到次优选的排序:托美丁钠、萘普生、布洛芬、芬洛芬钙。在20多项疗效指标中,除三项指标外,托美丁钠和萘普生是四种药物中疗效较好的一对,芬洛芬钙和布洛芬是疗效较差的一对。九项耐受性指标中的八项显示出以下从耐受性最好到最差的排序:布洛芬、萘普生、托美丁钠、芬洛芬钙、阿司匹林。本研究中比较的新型NSAI药物之间很少有差异达到统计学显著性。然而,这类研究中出现的耐受性-疗效关系有助于确定在风湿性疾病中使用这些药物的合理方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验